| Professional Services Industry | Industrials Sector | Pierre Boulud CEO | XDUS Exchange | - ISIN |
| FR Country | 14,147 Employees | 9 Jun 2025 Last Dividend | 20 Sep 2017 Last Split | - IPO Date |
bioMérieux S.A., originally known as B-D Mérieux, is a global leader in the development and production of in vitro diagnostic solutions, with a history dating back to 1963. Headquartered in Marcy-l'Étoile, France, the company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. Its main focus is on diagnosing infectious diseases, leveraging biological samples such as blood, saliva, and urine to detect a variety of bacterial, parasitic, and viral infections. Additionally, bioMérieux extends its expertise to the microbiological control of production environments in the food, pharmaceutical, and cosmetic industries, ensuring safety and compliance. A subsidiary of Institut Mérieux SA, bioMérieux S.A. serves a wide range of clients including clinical and hospital laboratories, physicians, blood banks, veterinarians, and industrial control laboratories, underlining its integral role in global health and safety industries.
bioMérieux's core offerings include systems designed for the diagnosis of infectious diseases. Utilizing biological samples, these systems can accurately diagnose a wide array of infections, from bacterial and parasitic to viral, ensuring timely and effective patient care.
For industries such as food, pharmaceutical, and cosmetics, bioMérieux provides solutions to monitor and control the microbiological quality of production processes and environments. This not only helps in ensuring product safety but also in adhering to regulatory standards.
This suite of software products and services is designed to collect, analyze, and merge various sources of data for informed decision-making. It exemplifies bioMérieux's commitment to advancing healthcare through technological innovation.
The company excels in the design, manufacture, and maintenance of instruments and software that are essential for conducting in vitro diagnostic tests. This ensures reliability and accuracy in diagnostics, which are critical for patient care.
bioMérieux also designs and manufactures reagents necessary for in vitro diagnostic tests. These high-quality reagents are crucial for the accuracy and reliability of diagnostic results, underpinning the company's reputation in healthcare diagnostics.